ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Infigratinib is provided as a single dose of minitablets for oral administration

Its studies are mostly in Achondroplasia, led by BridgeBio.

Furthest: phase 2, since Jun 23, 20251 company-led study, 1 open or runningNext primary completion: Mar 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBio11 open or runningphase 2since Jun 23, 2025Jun 23, 2025Mar 2030phase 2 · NCT07169279

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 23, 2025First study: phase 2 study in AchondroplasiaFirst studyNCT07169279 · 77 planned · United States, Australia, Canada and more

Ahead

  1. Mar 2030Primary completion: phase 2 study in AchondroplasiaNCT07169279

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07169279Achondroplasia · United States, Australia, Canada and more2RecruitingMar 203077

How it is read

Names in the registry

  • “Infigratinib is provided as a single dose of minitablets for oral administration”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.